Alan B. Lancz & Associates’s AbbVie ABBV Stock Holding History

Alan B. Lancz & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$957K	Sell	4,402 -722	-14%	-$160K	0.93%	23
2025 Q4	$1.17M	Hold	5,124	–	–	1.03%	20
2025 Q3	$1.19M	Hold	5,124	–	–	1.07%	20
2025 Q2	$951K	Hold	5,124	–	–	0.95%	28
2025 Q1	$1.07M	Sell	5,124 -100	-2%	-$19.4K	1.14%	20
2024 Q4	$928K	Sell	5,224 -400	-7%	-$73.5K	0.94%	22
2024 Q3	$1.11M	Sell	5,624 -150	-3%	-$28K	1.02%	22
2024 Q2	$990K	Buy	+5,774	New	+$956K	0.98%	21
2023 Q4	$956K	Hold	6,167	–	–	1%	23
2023 Q3	$919K	Sell	6,167 -307	-5%	-$45.1K	1.04%	21
2023 Q2	$872K	Hold	6,474	–	–	0.93%	24
2023 Q1	$1.03M	Hold	6,474	–	–	1.07%	19
2022 Q4	$994K	Hold	6,474	–	–	1%	20
2022 Q3	$869K	Hold	6,474	–	–	1.03%	21
2022 Q2	$929K	Sell	6,474 -486	-7%	-$74.3K	0.92%	25
2022 Q1	$1.13M	Hold	6,960	–	–	1%	23
2021 Q4	$942K	Buy	+6,960	New	+$822K	0.82%	26

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Alan B. Lancz & Associates's ABBV Position: Q1 2026 in Review

Alan B. Lancz & Associates reduced its AbbVie (ABBV) stake by 14% in Q1 2026, selling an estimated $160K and leaving 4,402 shares worth $957K. The position accounts for 0.93% of the portfolio, ranked #23.

Alan B. Lancz & Associates first reported a position in ABBV in Q4 2021 and has held it in 17 quarters since. The position peaked at $1.19M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Alan B. Lancz & Associates held 4,402 shares of AbbVie worth $957K as of Q1 2026.
Alan B. Lancz & Associates sold 722 AbbVie shares in Q1 2026, an estimated $160K.
AbbVie made up 0.93% of Alan B. Lancz & Associates's portfolio in Q1 2026, its #23 holding.
Alan B. Lancz & Associates first reported a position in AbbVie in Q4 2021 and has held it in 17 quarters since.
Alan B. Lancz & Associates's AbbVie position peaked at $1.19M in Q3 2025.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Alan B. Lancz & Associates's 13F filing for Q1 2026, filed 5 May 2026.